Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations

Valentina Vignali; Philip A Hines; Ana Glória Cruz; Barbara Ziętek; Ralf Herold

doi:10.3389/fmed.2022.1064003

Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations

Valentina Vignali, Philip A Hines^*, Ana Glória Cruz, Barbara Ziętek, Ralf Herold

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In medicines development, the progress in science and technology is accelerating. Awareness of these developments and their associated challenges and opportunities is essential for medicines regulators and others to translate them into benefits for society. In this context, the European Medicines Agency uses horizon scanning to shine a light on early signals of relevant innovation and technological trends with impact on medicinal products. This article provides the results of systematic horizon scanning exercises conducted by the Agency, in collaboration with the World Health Organization (WHO) and the European Commission's Joint Research Centre's (DG JRC). These collaborative exercises aim to inform policy-makers of new trends and increase preparedness in responding to them. A subset of 25 technological trends, divided into three clusters were selected and reviewed from the perspective of medicines regulators. For each of these trends, the expected impact and challenges for their adoption are discussed, along with recommendations for developers, regulators and policy makers.

Original language	English
Article number	1064003
Number of pages	20
Journal	Frontiers in medicine
Volume	9
DOIs	https://doi.org/10.3389/fmed.2022.1064003
Publication status	Published - 8 Dec 2022

Access to Document

10.3389/fmed.2022.1064003Licence: CC BY

Cite this

@article{892e0d0989a64288930be1aa15c1efcb,

title = "Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations",

abstract = "In medicines development, the progress in science and technology is accelerating. Awareness of these developments and their associated challenges and opportunities is essential for medicines regulators and others to translate them into benefits for society. In this context, the European Medicines Agency uses horizon scanning to shine a light on early signals of relevant innovation and technological trends with impact on medicinal products. This article provides the results of systematic horizon scanning exercises conducted by the Agency, in collaboration with the World Health Organization (WHO) and the European Commission's Joint Research Centre's (DG JRC). These collaborative exercises aim to inform policy-makers of new trends and increase preparedness in responding to them. A subset of 25 technological trends, divided into three clusters were selected and reviewed from the perspective of medicines regulators. For each of these trends, the expected impact and challenges for their adoption are discussed, along with recommendations for developers, regulators and policy makers.",

author = "Valentina Vignali and Hines, {Philip A} and Cruz, {Ana Gl{\'o}ria} and Barbara Zi{\c e}tek and Ralf Herold",

note = "Copyright {\textcopyright} 2022 Vignali, Hines, Cruz, Zi{\c e}tek and Herold.",

year = "2022",

month = dec,

day = "8",

doi = "10.3389/fmed.2022.1064003",

language = "English",

volume = "9",

journal = "Frontiers in medicine",

issn = "2296-858X",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Health horizons

T2 - Future trends and technologies from the European Medicines Agency's horizon scanning collaborations

AU - Vignali, Valentina

AU - Hines, Philip A

AU - Cruz, Ana Glória

AU - Ziętek, Barbara

AU - Herold, Ralf

PY - 2022/12/8

Y1 - 2022/12/8

N2 - In medicines development, the progress in science and technology is accelerating. Awareness of these developments and their associated challenges and opportunities is essential for medicines regulators and others to translate them into benefits for society. In this context, the European Medicines Agency uses horizon scanning to shine a light on early signals of relevant innovation and technological trends with impact on medicinal products. This article provides the results of systematic horizon scanning exercises conducted by the Agency, in collaboration with the World Health Organization (WHO) and the European Commission's Joint Research Centre's (DG JRC). These collaborative exercises aim to inform policy-makers of new trends and increase preparedness in responding to them. A subset of 25 technological trends, divided into three clusters were selected and reviewed from the perspective of medicines regulators. For each of these trends, the expected impact and challenges for their adoption are discussed, along with recommendations for developers, regulators and policy makers.

AB - In medicines development, the progress in science and technology is accelerating. Awareness of these developments and their associated challenges and opportunities is essential for medicines regulators and others to translate them into benefits for society. In this context, the European Medicines Agency uses horizon scanning to shine a light on early signals of relevant innovation and technological trends with impact on medicinal products. This article provides the results of systematic horizon scanning exercises conducted by the Agency, in collaboration with the World Health Organization (WHO) and the European Commission's Joint Research Centre's (DG JRC). These collaborative exercises aim to inform policy-makers of new trends and increase preparedness in responding to them. A subset of 25 technological trends, divided into three clusters were selected and reviewed from the perspective of medicines regulators. For each of these trends, the expected impact and challenges for their adoption are discussed, along with recommendations for developers, regulators and policy makers.

U2 - 10.3389/fmed.2022.1064003

DO - 10.3389/fmed.2022.1064003

M3 - Article

C2 - 36569125

SN - 2296-858X

VL - 9

JO - Frontiers in medicine

JF - Frontiers in medicine

M1 - 1064003

ER -